These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33096223)

  • 1. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.
    Nguyen VT; Rivière P; Ripoll P; Barnier J; Vuillemot R; Ferrand G; Cohen-Boulakia S; Ravaud P; Boutron I;
    J Clin Epidemiol; 2021 Feb; 130():107-116. PubMed ID: 33096223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
    Junqueira DR; Rowe BH
    Br J Clin Pharmacol; 2021 Apr; 87(4):1758-1767. PubMed ID: 33047848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.Gov.
    Sacks CA; North CM; Wolf M; Dougan M; Campbell KR; Moggridge J; Fralick M
    J Gen Intern Med; 2022 Jan; 37(1):154-161. PubMed ID: 34755268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatments for covid-19: living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
    BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis.
    Wang B; Lai J; Yan X; Jin F; Yi B; An C; Li Y; Yao C
    Drug Des Devel Ther; 2020; 14():5097-5108. PubMed ID: 33239868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial.
    Stoll F; Blank A; Mikus G; Czock D; Foerster KI; Hermann S; Häußler K; Muhareb A; Hummler S; Weiss J; Burhenne J; Haefeli WE
    Trials; 2020 Jun; 21(1):584. PubMed ID: 32600363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
    Pimentel J; Andersson N
    Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring trial publication and research waste in COVID-19 randomised trials of hydroxychloroquine, corticosteroids, and vitamin D: a meta-epidemiological cohort study.
    Fincham L; Hohlfeld A; Clarke M; Kredo T; McCaul M
    BMC Med Res Methodol; 2024 Jan; 24(1):19. PubMed ID: 38262938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.
    Calderón JM; Zerón HM; Padmanabhan S
    Trials; 2020 Jun; 21(1):504. PubMed ID: 32513231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.
    Asili P; Mirahmad M; Tabatabaei-Malazy O; Manayi A; Haghighat E; Mahdavi M; Larijani B
    Daru; 2021 Dec; 29(2):449-467. PubMed ID: 34762250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence mapping and analysis of registered COVID-19 clinical trials in China.
    Lu L; Li F; Wen H; Ge S; Zeng J; Luo W; Wang L; Tang C; Xu N
    BMC Med; 2020 Jun; 18(1):167. PubMed ID: 32493331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.